{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:31Z","timestamp":1793230651627,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59665-7","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:27:06Z","timestamp":1747225626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prolonging parathyroid hormone analog action in vitro and in vivo through peptide lipidation"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-2066","authenticated-orcid":false,"given":"Jakob","family":"H\u00f6ppner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-1596","authenticated-orcid":false,"given":"Hiroshi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju Krishnan","family":"Anitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9871-8333","authenticated-orcid":false,"given":"Ross W.","family":"Cheloha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-9778","authenticated-orcid":false,"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Bouxsein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-0058","authenticated-orcid":false,"given":"Samuel H.","family":"Gellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"J\u00fcppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-5772","authenticated-orcid":false,"given":"Thomas J.","family":"Gardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"59665_CR1","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrendo.2015.139","volume":"11","author":"RW Cheloha","year":"2015","unstructured":"Cheloha, R. W., Gellman, S. H., Vilardaga, J. P. & Gardella, T. J. PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat. Rev. Endocrinol. 11, 712\u2013724 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"59665_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11914-023-00793-8","volume":"21","author":"PJ Kostenuik","year":"2023","unstructured":"Kostenuik, P. J., Binkley, N. & Anderson, P. A. Advances in osteoporosis therapy: focus on osteoanabolic agents, secondary fracture prevention, and perioperative bone health. Curr. Osteoporos. Rep. 21, 386\u2013400 (2023).","journal-title":"Curr. Osteoporos. Rep."},{"key":"59665_CR3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jbmr.2811","volume":"7","author":"M Shimizu","year":"2016","unstructured":"Shimizu, M. et al. Pharmacodynamic actions of a long-acting PTH Analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys. J. Bone Miner. Res.\u00a07, 1405\u20131412 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"59665_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","volume":"38","author":"AA Khan","year":"2023","unstructured":"Khan, A. A. et al. Efficacy and safety of parathyroid hormone replacement with transcon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. J. Bone Miner. Res.\u00a038, 14\u201325 (2023).","journal-title":"J. Bone Miner. Res."},{"key":"59665_CR5","doi-asserted-by":"crossref","unstructured":"Bilezikian, J. P. et al. Hypoparathyroidism. J. Clinical Endocrinol. Metab. 105, 1722\u20131736 (2020).","DOI":"10.1210\/clinem\/dgaa113"},{"key":"59665_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","volume":"87","author":"J Satterwhite","year":"2010","unstructured":"Satterwhite, J. et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif. tissue Int. 87, 485\u2013492 (2010).","journal-title":"Calcif. tissue Int."},{"key":"59665_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bone.2018.09.018","volume":"120","author":"KK Winer","year":"2019","unstructured":"Winer, K. K. Advances in the treatment of hypoparathyroidism with PTH 1-34. Bone 120, 535\u2013541 (2019).","journal-title":"Bone"},{"key":"59665_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abc5944","volume":"14","author":"AD White","year":"2021","unstructured":"White, A. D. et al. Spatial bias in cAMP generation determines biological responses to PTH type 1 receptor activation. Sci. Signal. 14, eabc5944 (2021).","journal-title":"Sci. Signal."},{"key":"59665_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s42003-023-04966-0","volume":"6","author":"I Portales-Castillo","year":"2023","unstructured":"Portales-Castillo, I. et al. Altered signaling and desensitization responses in PTH1R mutants associated with Eiken syndrome. Commun. Biol. 6, 599 (2023).","journal-title":"Commun. Biol."},{"key":"59665_CR10","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.1074\/jbc.M009395200","volume":"276","author":"SR Hoare","year":"2001","unstructured":"Hoare, S. R., Gardella, T. J. & Usdin, T. B. Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor. effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation. J. Biol. Chem. 276, 7741\u20137753 (2001).","journal-title":"J. Biol. Chem."},{"key":"59665_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1210\/me.2007-0274","volume":"22","author":"T Dean","year":"2008","unstructured":"Dean, T., Vilardaga, J. P., Potts, J. T. Jr & Gardella, T. J. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrp) for distinct conformations of the PTH\/PTHrp receptor. Mol. Endocrinol. 22, 156\u2013166 (2008).","journal-title":"Mol. Endocrinol."},{"key":"59665_CR12","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1073\/pnas.1301674110","volume":"110","author":"A Maeda","year":"2013","unstructured":"Maeda, A. et al. Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc. Natl Acad. Sci. USA 110, 5864\u20135869 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59665_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley, G., Dean, T., Corbin, B. A., Bahar, H. & Gardella, T. J. Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling. Endocrinology 157, 141\u2013149 (2016).","journal-title":"Endocrinology"},{"key":"59665_CR14","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1210\/clinem\/dgae121","volume":"109","author":"I Takacs","year":"2024","unstructured":"Takacs, I. et al. An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist, in hypoparathyroidism. J. Clin. Endocrinol. Metab. 109, 2199\u20132209 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"59665_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10367","volume":"4","author":"H Noda","year":"2020","unstructured":"Noda, H. et al. Optimization of PTH\/PTHrP hybrid peptides to derive a long-acting PTH analog (LA-PTH). JBMR Plus 4, e10367 (2020).","journal-title":"JBMR Plus"},{"key":"59665_CR16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2212736119","volume":"119","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. Altered signaling at the PTH receptor via modified agonist contacts with the extracellular domain provides a path to prolonged agonism in vivo. Proc. Natl Acad. Sci. 119, e2212736119 (2022).","journal-title":"Proc. Natl Acad. Sci."},{"key":"59665_CR17","doi-asserted-by":"publisher","first-page":"14486","DOI":"10.1021\/jacs.9b04179","volume":"141","author":"S Liu","year":"2019","unstructured":"Liu, S. et al. Use of backbone modification to enlarge the spatiotemporal diversity of parathyroid hormone receptor-1 signaling via biased agonism. J. Am. Chem. Soc. 141, 14486\u201314490 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"59665_CR18","doi-asserted-by":"publisher","first-page":"8816","DOI":"10.1021\/acs.jmedchem.7b00876","volume":"60","author":"RW Cheloha","year":"2017","unstructured":"Cheloha, R. W. et al. Development of potent, protease-resistant agonists of the parathyroid hormone receptor with broad beta residue distribution. J. Med Chem. 60, 8816\u20138833 (2017).","journal-title":"J. Med Chem."},{"key":"59665_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nbt.2920","volume":"32","author":"RW Cheloha","year":"2014","unstructured":"Cheloha, R. W., Maeda, A., Dean, T., Gardella, T. J. & Gellman, S. H. Backbone modification of a polypeptide drug alters duration of action in vivo. Nat. Biotechnol. 32, 653\u2013655 (2014).","journal-title":"Nat. Biotechnol."},{"key":"59665_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jbmr.2917","volume":"32","author":"J Guo","year":"2017","unstructured":"Guo, J. et al. Prolonged pharmacokinetic and pharmacodynamic actions of a pegylated parathyroid hormone (1-34) peptide fragment. J. Bone Miner. Res. 32, 86\u201398 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"59665_CR21","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/jbmr.3824","volume":"34","author":"L Holten-Andersen","year":"2019","unstructured":"Holten-Andersen, L. et al. Design and preclinical development of transcon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism. J. Bone Miner. Res.\u00a034, 2075\u20132086 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"59665_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","volume":"15","author":"RM Gutgesell","year":"2024","unstructured":"Gutgesell, R. M., Nogueiras, R., Tschop, M. H. & Muller, T. D. Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes. Diab. Ther. 15, 1069\u20131084 (2024).","journal-title":"Diab. Ther."},{"key":"59665_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 10, 155 (2019).","journal-title":"Front Endocrinol."},{"key":"59665_CR24","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med Chem. 58, 7370\u20137380 (2015).","journal-title":"J. Med Chem."},{"key":"59665_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.molmet.2013.08.008","volume":"2","author":"BP Ward","year":"2013","unstructured":"Ward, B. P. et al. Peptide lipidation stabilizes structure to enhance biological function. Mol. Metab. 2, 468\u2013479 (2013).","journal-title":"Mol. Metab."},{"key":"59665_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1124\/molpharm.121.000270","volume":"100","author":"M Lucey","year":"2021","unstructured":"Lucey, M. et al. Acylation of the incretin peptide exendin-4 directly impacts glucagon-like peptide-1 receptor signaling and trafficking. Mol. Pharm. 100, 319\u2013334 (2021).","journal-title":"Mol. Pharm."},{"key":"59665_CR27","doi-asserted-by":"publisher","unstructured":"Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.140532. (2020).","DOI":"10.1172\/jci.insight.140532"},{"key":"59665_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16092","volume":"8","author":"A Zorzi","year":"2017","unstructured":"Zorzi, A., Middendorp, S. J., Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nat. Commun. 8, 16092 (2017).","journal-title":"Nat. Commun."},{"key":"59665_CR29","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.1039\/C5CC00301F","volume":"51","author":"Y Liu","year":"2015","unstructured":"Liu, Y. et al. Triblock peptide-linker-lipid molecular design improves potency of peptide ligands targeting family B G protein-coupled receptors. Chem. Commun. 51, 6157\u20136160 (2015).","journal-title":"Chem. Commun."},{"key":"59665_CR30","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1021\/acs.molpharmaceut.1c00149","volume":"18","author":"S Ruan","year":"2021","unstructured":"Ruan, S., Yang, G., Dong, Y., Shangguan, W. & Lu, W. Discovery of a Long-Acting Parathyroid Hormone 1-34 Analogue to Treat Hypoparathyroidism. Mol. Pharm. 18, 3260\u20133271 (2021).","journal-title":"Mol. Pharm."},{"key":"59665_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/jbmr.2769","volume":"31","author":"R Bi","year":"2016","unstructured":"Bi, R. et al. Diphtheria toxin- and GFP-based mouse models of acquired hypoparathyroidism and treatment with a long-acting parathyroid hormone analog. J. Bone Miner. Res.\u00a031, 975\u2013984 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"59665_CR32","doi-asserted-by":"publisher","first-page":"49003","DOI":"10.1074\/jbc.M106827200","volume":"276","author":"N Shimizu","year":"2001","unstructured":"Shimizu, N., Guo, J. & Gardella, T. Parathyroid hormone (1-14) and (1-11) analogs conformationally constrained by {alpha} aminoisobutyric acid mediate full agonist responses via the Juxtamembrane region of the PTH 1 receptor. J. Biol. Chem. 276, 49003\u201349012 (2001).","journal-title":"J. Biol. Chem."},{"key":"59665_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bone.2004.08.015","volume":"35","author":"RJ Murrills","year":"2004","unstructured":"Murrills, R. J. et al. In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity. Bone 35, 1263\u20131272 (2004).","journal-title":"Bone"},{"key":"59665_CR34","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1210\/me.2005-0349","volume":"20","author":"T Dean","year":"2006","unstructured":"Dean, T. et al. Mechanisms of ligand binding to the parathyroid hormone (PTH)\/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol. Endocrinol. 20, 931\u2013943 (2006).","journal-title":"Mol. Endocrinol."},{"key":"59665_CR35","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41594-018-0151-4","volume":"25","author":"J Ehrenmann","year":"2018","unstructured":"Ehrenmann, J. et al. High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist. Nat. Struct. Mol. Biol. 25, 1086\u20131092 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"59665_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1126\/science.aav7942","volume":"364","author":"L-H Zhao","year":"2019","unstructured":"Zhao, L.-H. et al. Structure and dynamics of the active human parathyroid hormone receptor-1. Science 364, 148\u2013153 (2019).","journal-title":"Science"},{"key":"59665_CR37","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1016\/j.molcel.2022.07.003","volume":"82","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi, K. et al. Endogenous ligand recognition and structural transition of a human PTH receptor. Mol. Cell 82, 3468\u20133483.e3465 (2022).","journal-title":"Mol. Cell"},{"key":"59665_CR38","doi-asserted-by":"publisher","unstructured":"Cary, B. P. et al. Molecular insights into peptide agonist engagement with the PTH receptor. Structure. https:\/\/doi.org\/10.1016\/j.str.2023.04.002. (2023).","DOI":"10.1016\/j.str.2023.04.002"},{"key":"59665_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"B Finan","year":"2015","unstructured":"Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27\u201336 (2015).","journal-title":"Nat. Med."},{"key":"59665_CR40","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Molecular insights into differentiated ligand recognition of the human parathyroid hormone receptor 2. Proc. Natl. Acad. Sci. 118, https:\/\/doi.org\/10.1073\/pnas.2101279118 (2021).","DOI":"10.1073\/pnas.2101279118"},{"key":"59665_CR41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbamem.2009.10.019","volume":"1798","author":"A Bouchet","year":"2010","unstructured":"Bouchet, A., Lairion, F. & Disalvo, E. A. Role of guanidinium group in the insertion of l-arginine in DMPE and DMPC lipid interphases. Biochimica et. Biophysica Acta (BBA) - Biomembranes 1798, 616\u2013623 (2010).","journal-title":"Biochimica et. Biophysica Acta (BBA) - Biomembranes"},{"key":"59665_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10441","volume":"5","author":"T Sato","year":"2021","unstructured":"Sato, T. et al. Comparable initial engagement of intracellular signaling pathways by parathyroid hormone receptor ligands teriparatide, abaloparatide, and long-acting PTH. JBMR Plus 5, e10441 (2021).","journal-title":"JBMR Plus"},{"key":"59665_CR43","doi-asserted-by":"publisher","unstructured":"Daley, E. J. et al. Actions of parathyroid hormone ligand analogues in humanized PTH1R knockin mice. Endocrinology 163, https:\/\/doi.org\/10.1210\/endocr\/bqac054 (2022).","DOI":"10.1210\/endocr\/bqac054"},{"key":"59665_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1210\/endrev\/bnab005","volume":"42","author":"TJ Martin","year":"2021","unstructured":"Martin, T. J., Sims, N. A. & Seeman, E. Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor, PTH1R. Endocr. Rev. 42, 383\u2013406 (2021).","journal-title":"Endocr. Rev."},{"key":"59665_CR45","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"LB Knudsen","year":"2000","unstructured":"Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med Chem. 43, 1664\u20131669 (2000).","journal-title":"J. Med Chem."},{"key":"59665_CR46","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","volume":"35","author":"JE Campbell","year":"2023","unstructured":"Campbell, J. E. et al. GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss\u2014chemistry, physiology, and clinical applications. Cell Metab. 35, 1519\u20131529 (2023).","journal-title":"Cell Metab."},{"key":"59665_CR47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bcp.13455","volume":"84","author":"D Tay","year":"2018","unstructured":"Tay, D., Cremers, S. & Bilezikian, J. P. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology. Br. J. Clin. Pharm. 84, 252\u2013267 (2018).","journal-title":"Br. J. Clin. Pharm."},{"key":"59665_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae045","volume":"8","author":"DB Hall","year":"2024","unstructured":"Hall, D. B., Kostyla, C. H., Hales, L. M. & Soliman, T. M. Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism. JBMR Plus\u00a08, ziae045 (2024).","journal-title":"JBMR Plus"},{"key":"59665_CR49","doi-asserted-by":"publisher","first-page":"14210","DOI":"10.1021\/jacs.9b05365","volume":"141","author":"PM Levine","year":"2019","unstructured":"Levine, P. M. et al. O-GlcNAc engineering of GPCR peptide-agonists improves their stability and in vivo activity. J. Am. Chem. Soc. 141, 14210\u201314219 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"59665_CR50","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1210\/endo.142.7.8253","volume":"142","author":"M Shimizu","year":"2001","unstructured":"Shimizu, M., Carter, P. H., Khatri, A., Potts, J. T. Jr & Gardella, T. J. Enhanced activity in parathyroid hormone-(1-14) and -(1-11): novel peptides for probing ligand-receptor interactions. Endocrinology 142, 3068\u20133074 (2001).","journal-title":"Endocrinology"},{"key":"59665_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34009-x","volume":"13","author":"X Zhai","year":"2022","unstructured":"Zhai, X. et al. Molecular insights into the distinct signaling duration for the peptide-induced PTH1R activation. Nat. Commun. 13, 6276 (2022).","journal-title":"Nat. Commun."},{"key":"59665_CR52","doi-asserted-by":"publisher","unstructured":"Zhao, L.-H. et al. Molecular recognition of two endogenous hormones by the human parathyroid hormone receptor-1. Acta pharmacologica Sinica. https:\/\/doi.org\/10.1038\/s41401-022-01032-z (2022).","DOI":"10.1038\/s41401-022-01032-z"},{"key":"59665_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28683-0","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao, F. et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat. Commun. 13, 1057 (2022).","journal-title":"Nat. Commun."},{"key":"59665_CR54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303696120","volume":"120","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Structural analysis of the dual agonism at GLP-1R and GCGR. Proc. Natl Acad. Sci. 120, e2303696120 (2023).","journal-title":"Proc. Natl Acad. Sci."},{"key":"59665_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109374","volume":"36","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Rep. 36, 109374 (2021).","journal-title":"Cell Rep."},{"key":"59665_CR56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116506119","volume":"119","author":"B Sun","year":"2022","unstructured":"Sun, B. et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc. Natl Acad. Sci. 119, e2116506119 (2022).","journal-title":"Proc. Natl Acad. Sci."},{"key":"59665_CR57","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/jbmr.4714","volume":"37","author":"JL Pasieka","year":"2022","unstructured":"Pasieka, J. L. et al. Etiology and pathophysiology of hypoparathyroidism: a narrative review. J. Bone Miner. Res.\u00a037, 2586\u20132601 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"59665_CR58","doi-asserted-by":"crossref","unstructured":"Carney, P., Cutler, G. B. Jr., Schneider, K., Zhang, F. & DiMarchi, R. MBX 2109, a Once-weekly parathyroid hormone replacement therapy prodrug: phase 1, first-in-human, randomized trial. J. Clin. Endocrinol. Metab. 110, 940\u2013950 (2024).","DOI":"10.1210\/clinem\/dgae808"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59665-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:55:55Z","timestamp":1786377355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59665-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59665"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59665-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article initially published, the Supplementary Methods (chemical synthesis) file was missing and is now included in the HTML version of the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HN, AK and TJG are inventors on a patent relating to lipid-modified PTH analogs (US patent # 11975050). The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"4487"}}